In our screen of various kinase inhibitors, we found the highly selective and potent GSK3 inhibitor CHIR99021 reduced expression levels of LGALS3 while not affecting EMT signature scores, suggesting it may be suitable for therapeutic investigation due to its possible specificity to LGALS3. GSK3 inhibition or downregulation can potentiate the cytotoxicity of CD8 + T cells against lymphoma cells86, gastric cancer cells87, and melanoma cells, with the latter also showing a blockage of LAG3 because of GSK3 targeting by small molecule inhibitors88. This evidence concerns the gene LGALS3 and lymphoma.